Send to

Choose Destination
J Asthma. 2018 Feb;55(2):208-219. doi: 10.1080/02770903.2017.1316394. Epub 2017 Jun 6.

Asthma control and disease burden in patients with asthma and allergic comorbidities.

Author information

a Health Outcomes Research, Kantar Health , Foster City , CA , USA.
b US Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp. , East Hanover , NJ , USA.
d Allergy and Respiratory Disease, Capital Allergy & Respiratory Disease Center , Sacramento , CA , USA.
c US Medical Affairs, Novartis Pharmaceuticals Corp., East Hanover , NJ , USA.



To assess asthma control and associations with health-related quality of life (HRQoL) and economic outcomes among patients with asthma and allergic comorbidities treated with inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) combination therapy.


Data from the 2011-2013 US National Health and Wellness Survey were used to identify patients with asthma currently treated with ICS and LABA combination therapy (N = 1923). Patients were included if they self-reported a physician diagnosis of asthma and at least one allergic/asthma-related comorbid condition (e.g., nasal allergies, atopic dermatitis). Asthma Control Test scores categorized patients as very poorly (scores ≤ 15; 29.3%), not well (16-19; 25.1%), or well controlled (20-25; 45.7%). Outcomes included HRQoL (SF-36v2; SF-12v2), work productivity and activity impairment, healthcare utilization (HRU), and annual indirect and direct costs. Generalized linear models, controlling for covariates, examined whether outcomes differed by asthma control.


Over half of the patients had very poorly or not well-controlled asthma (54.4%). Patients with very poorly controlled versus well-controlled asthma reported significantly greater decreases in HRQoL, greater overall work impairment, and higher HRU (all, p < 0.05). Very poorly controlled patients incurred over double the indirect costs and nearly one and a half times the direct and total costs of well-controlled patients.


Increasing level of asthma control was related to improved HRQoL and lower costs. The considerably high prevalence of uncontrolled asthma among patients on ICS and LABA suggests poor treatment adherence or unmet needs in current treatment and may require step-up therapy in appropriate patients according to clinical guidelines.


Costs; health-related quality of life; inhaled corticosteroids; long-acting beta-agonists; work productivity loss

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center